These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36232271)

  • 1. Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review.
    Abdul Halim AFN; Ahmad D; Miaw Yn JL; Masdor NA; Ramly N; Othman R; Kandayah T; Hassan MR; Dapari R
    Int J Environ Res Public Health; 2022 Oct; 19(19):. PubMed ID: 36232271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
    Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass drug administration for lymphatic filariasis elimination amidst COVID-19 pandemic in Odisha, India: A step towards achieving SDG-3.
    Sinha A; Mohapatra S; Mohanty S; Pati S; Sahoo PK
    Trop Doct; 2022 Oct; 52(4):556-559. PubMed ID: 35770893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya.
    Kusi C; Steinmann P; Merten S
    Infect Dis Poverty; 2020 Mar; 9(1):22. PubMed ID: 32114985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia.
    Silumbwe A; Halwindi H; Zulu JM
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007861. PubMed ID: 31774820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring factors affecting quality implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in Northern Ghana.
    Manyeh AK; Ibisomi L; Ramaswamy R; Baiden F; Chirwa T
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007009. PubMed ID: 32804967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
    Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
    Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar.
    Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Wood P; Wangdi K; McBride WJ
    Parasit Vectors; 2021 Jan; 14(1):72. PubMed ID: 33482891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
    Lupenza ET; Gasarasi DB; Minzi OM
    PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are census data accurate for estimating coverage of a lymphatic filariasis MDA campaign? Results of a survey in Sierra Leone.
    Kamara W; Zoerhoff KL; Toubali EH; Hodges MH; Bisanzio D; Chowdhury D; Sonnie M; Magbity E; Samai M; Conteh A; Macarthy F; Baker M; Koroma JB
    PLoS One; 2019; 14(12):e0224422. PubMed ID: 31856176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptance of Mass Drug Administration for Prophylaxis against Lymphatic Filariasis in a Tribal Endemic Area: A Descriptive Cross-sectional Study.
    Agarwal A; Maharshi V
    Indian J Public Health; 2024 Apr; 68(2):194-200. PubMed ID: 38953805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging the gap in outreach and compliance with mass drug administration for lymphatic filariasis elimination in an endemic district in Kerala, India: an intervention research approach.
    Nandha B; Meenakshy V; Abdul Khader N; Vijayakumar KN; Jambulingam P
    Health Educ Res; 2019 Jun; 34(3):300-309. PubMed ID: 30805648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eliminating Lymphatic Filariasis: Is it Worth it?
    Niessen LW; Taylor ML
    Clin Infect Dis; 2020 Jun; 70(12):2568-2569. PubMed ID: 31343066
    [No Abstract]   [Full Text] [Related]  

  • 14. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
    Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach.
    Njomo DW; Kibe LW; Kimani BW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008499. PubMed ID: 32936792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.
    de Souza DK; Gass K; Otchere J; Htet YM; Asiedu O; Marfo B; Biritwum NK; Boakye DA; Ahorlu CS
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008306. PubMed ID: 32407319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motivation-opportunity-ability-behaviour of community members and program implementers towards mass drug administration for lymphatic filariasis elimination in India: a systematic review and implementation priority.
    Sinha A; Mohapatra S; Sahoo KC; Mohanty S; Sahoo B; Pati S; Sahoo PK
    Trans R Soc Trop Med Hyg; 2024 Jul; 118(7):426-435. PubMed ID: 38506271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana.
    Biritwum NK; Garshong B; Alomatu B; de Souza DK; Gyapong M; Kyelem D
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005619. PubMed ID: 28493966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic Filariasis: A Systematic Review on Morbidity and Its Repercussions in Countries in the Americas.
    Medeiros ZM; Vieira AVB; Xavier AT; Bezerra GSN; Lopes MFC; Bonfim CV; Aguiar-Santos AM
    Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.